What’s new

• Growth target for FY27 lowered from previous doubling goal to 25-30%.
• Second-half revenue grew 41% to ₹80.1 cr; total FY26 revenue hit ₹146 cr.
• A 75,000 sq ft facility is expected to begin operations in August 2026.

Why it matters

Management abandoned its aggressive growth target after acknowledging gross margin compression. The company is trading speed for a shift in client mix, making the move to ₹450-500 cr by FY29 a harder climb.

What we’re watching

• Margin performance in the upcoming quarters.
• The August 2026 operational start date for the new facility.
• The next test is whether the FY29 revenue target holds.

The full read

Influx Healthtech tempered its growth outlook during its May 22 conference call. Management lowered the FY27 revenue target to 25-30% from a previous goal of doubling business. This revision follows a year with ₹146 cr in revenue, where second-half sales rose 41% to ₹80.1 cr. The firm is currently building a 75,000 sq ft facility expected to launch in August 2026. This capacity expansion and a deliberate client mix shift are the reasons behind the revision. Gross margins are feeling the impact of these changes. While a long-term goal of ₹450-500 cr by FY29 remains, the open question is how the company balances its capacity investment with the slower revenue trajectory. The next test is margin stability through this transition.

Primary source: NSE